BofA raised the firm’s price target on Cellebrite to $9 from $8 and keeps a Neutral rating on the shares. While the firm awaits more stable growth and profitability trends, it raised its price target on Cellebrite shares given the increase in sector multiples.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLBT: